Evidence map›Paper›PMID 39247617›Full record

ArticleFrontiers in psychiatry2024

Network pharmacology- and molecular docking-based investigation on the mechanism of action of Si-ni San in the treatment of depression combined with anxiety and experimental verification in adolescent rats.

Zhiping Li, Shimin Liang, Xulan Cui, Chongkun Shen, Zaibin Xu, Wei Chen, Mingan Wu, Chao Liang, Jinman Liu, Jiawen Huang and 1 more

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Food science & nutrition · 2025
    Article
  3. Article
  4. Frontiers in pharmacology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhiping Li *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shimin Liang *Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xulan Cui *Department of Pharmacy, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
Chongkun ShenSchool of Fundamental Medical Science, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zaibin XuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Wei ChenRehabilitation Center Massage Clinic, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Mingan WuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chao LiangDeparment of Acupuncture, Haikou Hospital of Traditional Chinese Medicine, Haikou, China.
Jinman LiuDepartment of Encephalopathy, Affiliated Jiangmen Traditional Chinese Medicine (TCM) Hospital of Ji'nan University, Jiangmen, China.
Jiawen HuangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Weirong LiScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence rate of adolescent depression and anxiety has been increasing since the outbreak of COVID-19, which there are no effective therapeutic drugs available. Si-ni San is commonly used in traditional Chinese medicine for the treatment of depression-like as well as anxiety-like behavior, but its mechanism for treating depression combined with anxiety during adolescence is not yet clear. Methods: Network pharmacology was used to explore potential drug molecules and related targets, molecular docking and molecular dynamics (MD) simulation were used to evaluate the interaction between the potential drug molecules and related targets, and a model of anxiety combined with depression in adolescent rats as well as the following behavioral tests and molecular biology tests were used to verify the results from network pharmacology and molecular docking. Results: As a result, 256 active ingredients of Si-ni San and 1128 potential targets were screened out. Among them, quercetin, Luteolin, kaempferol, 7-Methoxy-2-methyl isoflavone, formononetin showed to be the most potential ingredients; while STAT3, IL6, TNF, AKT1, AKT1, TP53, IL1B, MAPK3, VEGFA, CASP3, MMP9 showed to be the most potential targets. AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway and TNF signaling pathway, which are involved in anti-inflammation processes, showed to be the most probable pathways regulated by Si-ni San. Molecular docking and MD simulation between the compounds to inflammation-associated targets revealed good binding abilities of quercetin, Luteolin, kaempferol, nobiletin and formononetin to PTGS2 and PPARγ. In the experiment with adolescent rats, Si-ni San markedly suppressed early maternal separation (MS) combined with adolescent chronic unpredictable mild stress (CUMS)-induced depression combined with anxiety. The qPCR results further indicated that Si-ni San regulated the oxidative stress and inflammatory response. Conclusion: This study demonstrates that adolescent anxiety- and depression-like behavior induced by MS combined CUMS can be ameliorated by Si-ni San by improved inflammation in hippocampus via targeting TNF pathway and Nrf2 pathway, helping to reveal the mechanism of Si-ni San in treating adolescent depression combined with anxiety.

Indexed as

anxietychronic unpredictable mild stressdepressionmaternal separationmolecular dockingnetwork pharmacologySi-ni San

Identifiers

PMID39247617
PMCPMC11378754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.